360. A First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Neutralization Profile of Two Long-Acting Anti-SARS-CoV-2 Monoclonal Antibodies

Authors
Category Primary study
JournalOpen Forum Infectious Diseases
Year 2023
This article has no abstract
Epistemonikos ID: adf6c4f8bd14b945fdda715b60e955f303eb078f
First added on: Feb 17, 2025